
Opinion|Videos|March 26, 2024
Overview of ARPIs in the Treatment of Prostate Cancer
Author(s)Matthew Smith, MD, PhD, Brian Helfand, MD, PhD
Comprehensive insights on ARPIs (androgen receptor pathway inhibitors) for the treatment of prostate cancer, highlighting what influences treatment decisions and safety profiles of the available APRIs.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Cretostimogene Grenadenorepvec: Mechanism and Rationale
5













